|Home | About | Journals | Submit | Contact Us | Français|
Osteoporosis, the main clinical consequence of which is osteoporotic fracture, affects 1 in 6 Canadian women over the age of 50.1 About 40% of white women 50 years of age in Canada will have an osteoporotic fracture during their remaining lifetime: 15.6% will experience a vertebral fracture, 16.0% a wrist fracture and 17.5% a hip fracture.2
The recommendations in this statement apply to most postmenopausal women in the general population, including those who have late menarche, early menopause, low calcium intake, low physical activity, high alcohol or caffeine intake, low body weight, a family history of osteoporosis or osteoporotic fractures or a history of hyperthyroidism or who are smokers. However, they do not apply to women who have specific conditions that predispose them to significant increased risk of fractures, including women taking steroids, those with hyperparathyroidism and those in nursing homes. These recommendations are meant to guide physicians in their discussions with their postmenopausal patients, as each individual woman may have unique risks and preferences. The recommended age for initiation of screening is based on the prevalence of osteoporosis and fractures among postmenopausal women in the different age groups.
Our recommendations are based on fracture data rather than on bone mineral density (BMD) data, since we do not know how short-term BMD differences translate into long-term fracture outcomes, especially among women without osteoporosis. A unique feature of our guideline is that we do not recommend using drug therapy for the primary prevention of osteoporosis, especially in young postmenopausal women. More than 45% of postmenopausal women have osteopenia.1 The fracture risk for most of these women is low. Because risk of fracture increases with age, it may be reasonable to consider prescribing drug therapy for women who are 65 years or older and who have a T score below –2.0.
The US Preventive Services Task Force recommends that women 65 years or older be screened routinely for osteoporosis and that those at increased risk of osteoporotic fractures (see Box 1) begin screening at age 60 (grade B recommendation).4
The recent Osteoporosis Society of Canada guidelines recommend screening with DEXA (dual energy x-ray absortiometry) for postmenopausal women who have 1 major and 2 minor clinical factors (Box 1) or those 65 years and older.5 They also recommend using bisphosphonates and raloxifene as first-line therapy for the prevention and treatment of osteoporosis, HRT as first-line therapy for the prevention of osteoporosis and as second-line therapy for the treatment of osteoporosis (although risks may outweigh benefits) and nasal calcitonin therapy as second-line therapy for the treatment of osteoporosis. In addition, they recommend using parathyroid hormone as first-line therapy for the treatment of severe osteoporosis.
The Society of Obstetricians and Gynaecologists of Canada (SOGC) guidelines, published before the release of the Women's Health Initiative (WHI) results, recommend using HRT, raloxifene and the bisphosphonates (all grade I recommendations) as well as calcium and vitamin D supplementation and exercise (all grade II recommendations) for the primary prevention of osteoporosis. They also recommend raloxifene, alendronate, risedronate, calcitonin and combination therapy (all grade I recommendations) and HRT and etidronate (grade II recommendations) for the treatment of osteoporosis. Since publication of the WHI results, the SOGC has revised its recommendation on combined estrogen–progestin therapy, stating that the overall risks may outweigh the benefits for postmenopausal women without menopausal symptoms and that other therapies should be considered first.6
Contributors: Angela Cheung authored the original systematic evidence review, drafted the current article and made subsequent revisions. Denice Feig, Moira Kapral, Natalia Diaz-Granados and Sylvie Dodin coauthored the original systematic evidence review, critically reviewed the current article and reviewed subsequent revisions. The Canadian Task Force on Preventive Health Care critically reviewed the evidence and developed the recommendations according to its methodology and consensus development process.
Competing interests: Angela Cheung has received honoraria to participate in CME events partially or fully supported by Eli Lilly, Merck, Proctor & Gamble, Aventis and Novartis; these companies have also contributed unrestricted educational grants in support of Toronto City-wide Osteoporosis Rounds, which Angela Cheung chairs. Natalia Diaz-Granados received a University Health Network/Merck Osteoporosis Scholarship in support of her Master's degree in epidemiology and her thesis work on predictors of osteoporosis in men. No competing interests declared for Moira Kapral, Sylvie Dodin or the members of the Canadian Task Force on Preventive Health Care.
Correspondence to: Canadian Task Force on Preventive Health Care, 117–100 Collip Circle, London ON N6G 4X8; fax 519 858-5112; gro.chpftc@ftc